0.01
+2.38%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evofem Biosciences
From its filings with the US Securities and Exchange Commission
Evofem Biosciences is based in San Diego, California and is incorporated in Delaware. Its shares trade on OTC under the ticker EVFM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $20.2m and net income of $391,000. At that date it held total assets of $20.3m and shareholders' equity of −$74.3m.
No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023.
U.S. is the largest commercial market worldwide and presents the greatest opportunity for PHEXX and other women’s health products.
J. Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023. NCHS Data Brief Number 539. August 2025.
539. August 2025. Accessed Jan. 9, 2026, via https://www.cdc.gov/nchs/data/databriefs/db539.pdf.
We believe PHEXX can be prescribed to help prevent unintended pregnancy in these patients.
The quick and easy pre-sex application is designed with spontaneity and convenience in mind.
Health Survey. Nov 22, 2024. Accessed Jan 7, 2026, via https://www.kff.org/womens-health-policy/contraceptive-experiences-coverage-and-preferencesfindings-from-the-2024-kff-womens-health-survey/#:~:text=Eight%20in%20ten%20(82%25)%20women,Almost%20half%20(48%25)%20of%20contraceptive.
E, et al. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception.
3,000 HCPs within the OB/GYN space, with a particular focus on current SOLOSEC prescribers and established relationships of our experienced sales team.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Nov 2014
- Employees
- 147
- Website
- evofem.com ↗
- Head office
- 12400 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Saundra PelletierInterim Chairman of the Board of Directors, President, Chief Executive Officer, since 2018$1.2m
- Ms. Ivy ZhangChief Financial Officer, Secretary$695,261
- Dr. Kim KamdarIndependent Director$78,750
- Mr. Tony O'BrienIndependent Director$75,000
- Dr. Lisa RarickIndependent Director$55,000
- Mr. Colin RutherfordIndependent Director$70,000
- Ms. Amy RaskopfChief Business Development Officer, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 20
- Environment
- 5
- Social
- 18
- Governance
- 38
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is commercial-stage biopharmaceutical with focus on women's sexual and reproductive health.
- Product Phexxi vaginal gel is an on-demand prescription contraceptive gel for women.
- Pipeline includes EVO100 for STI prevention and EVO200 for bacterial vaginosis reduction.
Weaknesses
- Company has only one commercial product, Phexxi vaginal gel.
- Company employs 147 full-time employees, which may limit operational scale.
- Company is engaged in developing multiple products but has no other commercialized products.
Opportunities
- Growing market for women's sexual and reproductive health products.
- Potential for EVO100 to address STI prevention needs.
- EVO200 could target recurrent bacterial vaginosis treatment market.
Threats
- Competition in women's sexual and reproductive health market.
- Regulatory challenges for new product approvals.
- Dependence on single commercial product for revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.